Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037


Delayed Nasdaq  -  04:00 2022-11-30 pm EST
305.17 USD   +4.72%
05:47pWall Street ends sharply higher after Powell comments
05:00pHealth Care Up as Biogen, Horizon Surge -- Health Care Roundup
04:22pWall Street ends sharply higher after Powell comments
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wall Street bounces back as Treasury yields dip

09/28/2022 | 02:29pm EST

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window.)


Apple drops on move to drop iPhone production boost


Treasury prices rebound after BoE decision


Biogen soars on landmark Alzheimer's data


Indexes: Dow +1.50%, S&P 500 +1.48%, Nasdaq +1.33%

Sept 28 (Reuters) - Wall Street rebounded strongly on Wednesday following its recent sell-off, helped by easing Treasury yields, while Apple dropped on concerns about demand for iPhones.

The gains came after the S&P 500 on Tuesday closed at its lowest since late 2020, dragging U.S. stocks further into bear market territory.

Stocks climbed as the yield on U.S. Treasuries came off decade highs that in recent sessions made interest rate-sensitive companies less attractive to investors.

Helping push Treasury yields lower, the Bank of England said it would buy long-dated British bonds in a move aimed at restoring financial stability in markets rocked globally by the fiscal policy of the new government in London.

"The yield on the two-year Treasury has gone up persistently over the course of the last several weeks, and for the first time we've seen it go down for two days in a row, and that has given equities a breather," said Art Hogan, chief market strategist at B. Riley Wealth.

Investors have also been keenly listening to comments from Federal Reserve officials on the path of monetary policy, with Atlanta Fed President Raphael Bostic on Wednesday backing another 75-basis-point interest rate hike in November.

U.S. stocks have been battered this year by worries that an aggressive push by the Fed to raise borrowing costs could throw the economy into a downturn.

Apple Inc lost 2.9% after Bloomberg reported the company is dropping plans to increase production of its new iPhones this year after an anticipated surge in demand failed to materialize.

Traders exchanged almost $15 billion worth of Apple shares, more than any other stock.

All of the 11 S&P 500 sector indexes rose, led by a 3.1% jump in energy and a 2.8% rise in communication services .

With Wednesday's gains, the S&P 500 is down about 22% so far in 2022.

In afternoon trading, the Dow Jones Industrial Average was up 1.5% at 29,573.27 points, while the S&P 500 gained 1.48% to 3,701.4.

The Nasdaq Composite added 1.33% to 10,973.41.

Biogen Inc surged 37% after saying its experimental Alzheimer's drug, developed with Japanese partner Eisai Co Ltd , succeeded in slowing cognitive decline.

Eli Lilly & Co, which is also developing an Alzheimer's drug, rose 6.8% and was among the biggest boosts to the S&P 500 index.

Advancing issues outnumbered declining ones on the NYSE by a 5.92-to-1 ratio; on Nasdaq, a 3.81-to-1 ratio favored advancers.

The S&P 500 posted one new 52-week high and 30 new lows; the Nasdaq Composite recorded 22 new highs and 203 new lows.

(Reporting by Noel Randewich in San Francisco and Shreyashi Sanyal, Susan Mathew and Ankika Biswas in Bengaluru; Editing by Vinay Dwivedi, Arun Koyyur and Jonathan Oatis)

ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 4.72% 305.17 Delayed Quote.27.20%
EISAI CO., LTD. 4.44% 9775 Delayed Quote.37.62%
All news about BIOGEN INC.
05:47pWall Street ends sharply higher after Powell comments
05:00pHealth Care Up as Biogen, Horizon Surge -- Health Care Roundup
04:22pWall Street ends sharply higher after Powell comments
04:20pBiogen, Wayfair rise; CrowdStrike, NetApp fall
04:00pWall Street ends sharply higher after Powell comments
03:19pEisai, Biogen Alzheimer's drug could be available to some next year
02:27pWall Street rallies after Powell eyes slower rate hikes
02:15pWall Street rises after Powell eyes slower rate hikes
12:34pDow dips ahead of Powell speech; Nasdaq kept afloat by growth stocks
11:34aGlobal markets live: Apple, Tesla, Boeing, HP, Intuit...
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 10 067 M - -
Net income 2022 2 904 M - -
Net Debt 2022 266 M - -
P/E ratio 2022 15,0x
Yield 2022 -
Capitalization 43 945 M 43 945 M -
EV / Sales 2022 4,39x
EV / Sales 2023 4,35x
Nbr of Employees 9 610
Free-Float 85,2%
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 305,17 $
Average target price 315,77 $
Spread / Average Target 3,47%
EPS Revisions
Managers and Directors
Christopher A. Viehbacher President, Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP